Later on, the compound, as well as other smaller molecules, was screened for more advancement by Hungarian agency Biorex, which was marketed to CytRx Company, who developed it toward a different route from 2003. The safety and efficacy of IQIRVO in patients with decompensated cirrhosis haven't been proven. Utilization of https://arthurp887ngx9.wikiusnews.com/user